It is called Ruxolitinib and is the drug that is being tested in Calabria for the treatment of patients affected by the Covid-19 virus. The experimental therapy started a few days ago and was authorized by the regional ethics committee.
The infectious diseases department of theAnnunziata hospital in Cosenza. Specifically, the study was designed by doctors Francesco Mendicino and Ciro Botta of the Hematology unit of Cosenza. Professor Marco Rossi of the Magna Graecia University of Catanzaro will also assist the teame
In Calabria, the experimentation to eradicate the contagion successfully starts
Calabria is the first region in Italy to have requested and obtained to be able to use Ruxolitinib to treat patients with Covid-9. The drug is used in hematology for chronic myeloproliferative syndromes. In the infectious diseases department of the Annunziata there are three patients undergoing therapy with Ruxolitinib. And, according to what was found by health professionals, improvements in the evolution of the disease would already be seen.
With the administration of this drug, the three subjects are showing a positive reaction to Covid-19 which bodes well for a full recovery. Of course the community all scientifically proceeds with caution in the application of the therapy. Doctors and health managers do not indulge in easy enthusiasm. However, given the first encouraging results, the trial will certainly be extended to other patients. This is confirmed by the Department of Health Protection, Health Policies of the Calabria Region.
Ruxolitinib, the anticancer drug that works with Covid-19 patients
Ruxolitinib belongs to the group of targeted anticancer drugs or tumor growth inhibitors. The molecules of which the drug is composed act in a more selective way than the classic chemotherapy therapy.
In the trial with Ruxolitinib in the three Cosenza patients, the clinical and laboratory data improvement bodes well. In fact, two of the three infected subjects, subjected to this particular therapy, no longer needed oxygen after two days of treatment. For Calabria, a region with a very fragile health system characterized by serious problems, it is definitely a result of considerable importance.
# Italian in the heart
